The Botanix (ASX:BOT) share price jumped 20% today

This cannabis focused biotech company was on form on Friday…

| More on:
rising asx share price represented by happy woman dancing excitedly

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price was a very strong performer on Friday.

The clinical stage synthetic cannabinoid company's shares ended the day a massive 20% higher at 7.8 cents.

However, despite this strong gain, the Botanix share price is still down 40% since the start of the year.

Why did the Botanix share price rocket higher?

With no news out of the company, today's gain in the Botanix share price is a bit of a mystery.

However, as I mentioned above, with its shares down by materially since the start of the year, some investors may believe they had fallen to an attractive level. Especially given some of its promising studies that are currently underway.

One of those is the BTX 1204 Pilot Study. BTX 1204A is a new higher dose formulation of synthetic cannabidiol (CBD) for atopic dermatitis. It leverages the company's Permetrex formulation used in the recent successful BTX 1801 Phase 2a study.

Management notes that results from a pilot study of canines with atopic dermatitis provides encouraging data to support further investigation. It also provides a clinically efficient approach to inform progression to further human studies.

What else has been happening?

Optimism over the aforementioned BTX 1801 Phase 2a study could also be giving the Botanix share price a lift. A recent update revealed that BTX 1801 was safe, well tolerated, clinically effective, and successful at achieving decolonisation of Staph aureus in the nose.

The success of this study has seen the company launch the next phase of BTX 1801 development, targeting the nasal decolonisation of Staph aureus in haemodialysis patients to prevent bloodstream infections.

Management highlights that there is an urgent need and significant market opportunity for novel approaches to prevent bloodstream infections in haemodialysis patients. Positively, plans for a Phase 2b clinical study are well advanced and can be fully funded with existing capital reserves.

Some investors may be hoping positive updates relating to these studies will keep the Botanix share price heading in the right direction during the second half of the year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Why Capricorn Metals, Insignia, Perseus Mining, and Qoria shares are storming higher

These shares are having a strong session on Tuesday. But why?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Amaero, AMP, Block, and South32 shares are racing higher today

These shares are starting the week on a positive note. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »